Daily Sepsis Research Analysis
Analyzed 76 papers and selected 3 impactful papers.
Summary
Three high-impact sepsis studies stood out today: a mechanistic Cell Reports paper uncovering a hypothalamic vasopressin circuit by which procalcitonin disrupts fluid balance; a large multicenter JAMA Network Open cohort associating ≥30 mL/kg early fluids with lower mortality across key sepsis subgroups; and a multicenter RCT in Critical Care showing no significant mortality benefit with HA-330 hemoadsorption in catecholamine-dependent septic shock. Together, they refine pathophysiology, confirm pragmatic resuscitation thresholds, and temper expectations for extracorporeal cytokine removal.
Research Themes
- Neuroendocrine mechanisms of fluid imbalance in sepsis (procalcitonin–VMPO–vasopressin circuit)
- Early fluid resuscitation thresholds and outcomes across comorbidity strata
- Efficacy and timing of extracorporeal cytokine removal in septic shock
Selected Articles
1. A hypothalamic VMPO-supraoptic vasopressin circuit mediates procalcitonin-induced fluid imbalance.
This mechanistic study shows that systemic procalcitonin crosses the blood-brain barrier and activates calcitonin receptors on Oprk1+ neurons in the hypothalamic VMPO, engaging a VMPO–supraoptic vasopressin circuit that perturbs fluid homeostasis. The work reframes PCT from a passive biomarker to an active mediator of dysnatremia and fluid imbalance in sepsis.
Impact: It provides first-in-kind central neuroendocrine mechanism linking a widely used sepsis biomarker (PCT) to fluid imbalance, opening therapeutic avenues targeting calcitonin receptors or downstream vasopressin pathways.
Clinical Implications: Reconceptualizes PCT as a potential driver of dysnatremia/volume derangements; suggests that antagonizing calcitonin-receptor signaling or modulating VMPO–vasopressin circuits might mitigate fluid imbalance in sepsis. Also cautions that exogenous PCT dynamics could have physiological effects.
Key Findings
- Systemic procalcitonin traverses the blood-brain barrier.
- Procalcitonin activates calcitonin receptors and depolarizes Oprk1-expressing VMPO neurons.
- A VMPO–supraoptic nucleus vasopressin circuit mediates PCT-induced disruption of fluid homeostasis.
Methodological Strengths
- Mechanistic dissection of a defined hypothalamic circuit with receptor-level specificity
- Direct demonstration of blood–brain barrier traversal by procalcitonin
Limitations
- Preclinical mechanistic work; human translational validation not detailed in the abstract
- Magnitude and temporal dynamics of PCT effects in clinical sepsis remain to be quantified
Future Directions: Validate the VMPO–vasopressin pathway in human sepsis, test calcitonin-receptor antagonists or neuromodulation strategies, and quantify PCT–osmoregulation dynamics in vivo.
Sepsis is a life-threatening condition characterized by infection-induced organ dysfunction, with fluid imbalance and cardiovascular instability as cardinal features. Although circulating procalcitonin (PCT) is widely used as a diagnostic and prognostic marker in sepsis, its pathophysiological role remains poorly understood. Here, we identify a central neural circuit through which PCT directly disrupts fluid homeostasis: systemic PCT crosses the blood-brain barrier, activates calcitonin receptors, and depolarizes the Oprk1-expressing neurons in the ventromedial preoptic nucleus of the hypothalamus (VMPO
2. Comorbidities, Weight-Based Initial Fluid Resuscitation, and Mortality in Patients With Sepsis.
In 25,481 adults with community-onset sepsis and an indication for fluids, administering ≥30 mL/kg within 6 hours was associated with lower adjusted 30-day mortality in patients with hypoperfusion or intermediate lactate elevation without severe cardiac/renal comorbidities. In those with severe comorbidities, effects were not statistically significant, though spline analyses suggested decreasing mortality beyond the 30 mL/kg threshold.
Impact: This large, contemporary, multicenter analysis directly informs ongoing debates on fluid volumes in early sepsis resuscitation, including patients with cardiac/renal vulnerabilities.
Clinical Implications: Supports ≥30 mL/kg within 6 hours for most patients with sepsis-induced hypoperfusion or intermediate lactate, while emphasizing individualized assessment in severe cardiac/renal comorbidities.
Key Findings
- Among patients without severe cardiac/renal comorbidities and hypoperfusion, ≥30 mL/kg was associated with a -4.4 pp adjusted absolute mortality difference.
- In intermediate lactate elevation without severe comorbidities, ≥30 mL/kg was associated with -1.8 pp adjusted mortality difference.
- In hypoperfusion with severe comorbidities, mortality differences were not statistically significant, though spline models suggested decreasing mortality with ≥30 mL/kg.
Methodological Strengths
- Large multicenter cohort across 67 hospitals with prespecified subgroups
- Weighted regression and spline models to address dose–response relationships
Limitations
- Observational design susceptible to residual confounding and treatment-selection bias
- Smaller high-risk comorbidity strata limited power for definitive subgroup conclusions
Future Directions: Prospective trials or advanced causal inference to validate thresholds in severe comorbidity phenotypes; integration with dynamic perfusion-guided targets.
IMPORTANCE: Guidelines suggest administering at least 30 mL/kg of initial fluid to patients with sepsis-induced hypoperfusion. However, there is uncertainty regarding the benefits of fluid resuscitation in patients with severe cardiac or kidney comorbidities or intermediate elevation of lactate level (18.0-36.0 mg/dL). OBJECTIVE: To evaluate the association of 30 mL/kg or more of fluid administered within 6 hours of hospital arrival with 30-day mortality across key target populations with community-onset sepsis. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included adults hospitalized for community-onset sepsis in 67 hospitals in the Michigan Hospital Medicine Safety Consortium (discharge dates from December 2021 to January 2025) who had an indication for fluid resuscitation (ie, hypotension or lactate level of 18.0 mg/dL or greater) within 3 hours of hospital arrival. Data were analyzed from November 26, 2024, to November 16, 2025. EXPOSURE: Receipt of at least 30 mL/kg vs less than 30 mL/kg fluid in the first 6 hours after hospital arrival. Fluid volume included all crystalloid fluid and blood products. MAIN OUTCOMES AND MEASURES: Association between administration of 30 mL/kg or more of fluid within 6 hours of hospital arrival and 30-day mortality using weighted regression models adjusted for patient characteristics. Target populations were defined by (1) fluid indication: hypoperfusion (hypotension or lactate level >36.0 mg/dL) vs intermediate lactate elevation (18.0-36.0 mg/dL) and (2) presence of severe comorbidities that might increase risk of fluid overload (left ventricular ejection fraction <40%, severe-to-critical aortic stenosis, or end-stage kidney disease). Secondary analyses used adjusted logistic regression models with restricted cubic spline terms to evaluate associations of fluid volume administered with mortality. RESULTS: Among 43 321 patients hospitalized for community-onset sepsis, 25 481 (58.8%) had an indication for fluid resuscitation and were included in the study (median age, 71 years [IQR, 61-80 years]; 50.5% male; 37.0% with body mass index >30.0, calculated as weight in kilograms divided by height in meters squared). A total of 12 943 (50.8%) had hypoperfusion without severe comorbidities; 1741 (6.8%), hypoperfusion with severe comorbidities; 9974 (39.1%), intermediate lactate elevation without severe comorbidities; and 823 (3.2%), intermediate lactate elevation with severe comorbidities. Administration of 30 mL/kg or more of fluid vs less than 30 mL/kg was associated with lower adjusted 30-day mortality rates in patients with hypoperfusion without severe comorbidities (26.0% [95% CI, 24.9%-27.2%] vs 30.4% [95% CI, 28.8%-32.0%]; adjusted absolute difference [diff], -4.4 percentage points [pp] [95% CI, -6.1 to -2.7 pp]) and intermediate lactate elevation without severe comorbidities (12.0% [95% CI, 10.6%-13.5%] vs 13.9% [95% CI, 12.9%-14.8%]; diff, -1.8 pp [95% CI, -3.6 to -0.1 pp]). For patients with hypoperfusion and severe cardiac or kidney comorbidities, the association between 30-day adjusted mortality and receiving 30 mL/kg or more of fluid vs less than 30 mL/kg was not statistically significant (34.7% [95% CI, 30.8%-38.6%] vs 38.8% [95% CI, 35.8%-41.8%]; diff, -4.1 pp [95% CI, -9.0 to 0.8 pp]), although spline models indicated decreasing mortality with fluid resuscitation of 30 mL/kg or more of fluid. CONCLUSIONS AND RELEVANCE: In this cohort study of patients with community-onset sepsis, initial administration of 30 mL/kg or more of fluid was associated with lower 30-day mortality among patients who had either hypoperfusion or intermediate lactate elevation without severe cardiac or kidney comorbidities. The findings suggest that broader application of at least 30 mL/kg of initial fluid resuscitation for sepsis in patients with hypoperfusion and cardiac or kidney comorbidities or intermediate lactate elevation may reduce sepsis-related mortality.
3. HA-330 hemoadsorption in septic shock requiring high-dose norepinephrine: a multicenter randomized controlled trial (CLEANSE).
In a multicenter RCT (n=128) of septic shock requiring ≥0.2 mcg/kg/min norepinephrine, two 3-hour HA-330 hemoadsorption sessions did not significantly reduce 28-day mortality versus standard care, nor improve key secondary endpoints. Post-hoc adjusted analyses suggested a potential signal, but the early-terminated trial was underpowered.
Impact: Provides randomized evidence counterbalancing uncontrolled reports of benefit for hemoadsorption, sharpening patient selection and trial design for extracorporeal immunomodulation.
Clinical Implications: Routine HA-330 use in catecholamine-dependent septic shock is not supported; use should be restricted to trials or carefully selected phenotypes until adequately powered studies confirm benefit.
Key Findings
- No statistically significant reduction in 28-day mortality with HA-330 vs standard care (RR 0.76; P=0.16; HR 0.68; P=0.09).
- No significant differences in organ support-free days, shock reversal, vasopressor dose, or inflammatory markers.
- Post-hoc adjusted Cox model (adjusting for IL-6 and VIS) suggested a hazard ratio of 0.62 (P=0.037), hypothesis-generating only.
Methodological Strengths
- Randomized, multicenter design with predefined primary endpoint
- Safety monitored with no serious adverse events reported
Limitations
- Early termination leading to underpowering and potential type II error
- Post-hoc adjusted findings risk overinterpretation; limited external generalizability (two centers)
Future Directions: Adequately powered, phenotype-enriched RCTs with biomarker-guided selection (e.g., IL-6, renin) and standardized dosing/timing to clarify effect heterogeneity.
BACKGROUND: Inflammatory cytokines play a pivotal role in septic shock, driving tissue injury and circulatory failure. Hemoadsorption has been proposed as an extracorporeal strategy that removes inflammatory mediators. Patient selection and treatment timing may be integral to clinical benefit. OBJECTIVES: To determine whether adjunctive hemoadsorption with the HA-330 cytokine adsorber reduces 28-day mortality in patients with septic shock requiring high-dose vasopressors, compared with standard treatment alone. METHODS: This multicenter, randomized controlled trial enrolled patients with septic shock requiring norepinephrine ≥ 0.2 mcg/kg/min at two tertiary care centers in Thailand. Participants were assigned 1:1 to standard treatment alone (ST group) or standard treatment with two 3-hour sessions of hemoadsorption using HA-330 (HA group). The primary outcome was 28-day mortality. The trial was terminated early at the second pre-planned interim analysis due to slow recruitment and funding constraints before reaching the planned sample size of 206 participants. RESULTS: A total of 128 participants were enrolled; 65 were assigned to the ST group and 63 to the HA group. The median age was 67 years, and baseline characteristics were largely comparable between groups. By day 28, 38 of 65 (58%) participants in the ST group and 28 of 63 (44%) in the HA group had died (relative risk, 0.76; 95% CI, 0.54-1.07; P = 0.16; hazard ratio, 0.68; 95% CI, 0.44-1.07; P = 0.09). No significant differences were observed in organ support-free days, shock reversal, vasopressor doses, or inflammatory markers. In a post-hoc Cox model adjusted for IL-6 (log-transformed) and VIS at hour 0, the hazard ratio for 28-day mortality was 0.62 (95% CI, 0.39-0.97; P = 0.037). No serious adverse events were reported in either group. CONCLUSIONS: In this randomized trial which was terminated early, adjunctive hemoadsorption with HA-330 in patients with septic shock requiring high-dose vasopressors did not statistically reduce 28-day mortality. TRIAL REGISTRATION: ClinicalTrials.gov (NCT05136183); registered November 29, 2021.